Ghassan T. Wahbeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ghassan T. Wahbeh has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- David L. Suskind
University of Washington School of Medicine , Seattle, WA 98109
4 shared publications Dale Lee
Seattle Children’s Hospital, University of Washington
2 shared publications- Karen F. Murray
Seattle Children’s Hospital
2 shared publications - Adam B. Goldin
Division of Pediatric General and Thoracic Surgery, Seattle Children's Hospital, Seattle, Washington
1 shared publication Amanda Bradshaw
Seattle Children’s Hospital
1 shared publication- Arlene K. Libby
Division of Pediatric General and Thoracic Surgery, Seattle Children's Hospital, 4800 Sand Point Way NE, Seattle, Washington, 98105, United States
1 shared publication
Latest Publications
- Open Access
- 5 December 2024
- Published by Wolters Kluwer Health in Saudi Journal of Gastroenterology
- Vol. 31 (2) , 51-52
Editorial: The safety and efficacy of ustekinumab in anti-TNFα refractory pediatric inflammatory bowel disease
- 5 December 2024
- Published by Wolters Kluwer Health in Saudi Journal of Gastroenterology
- Vol. 31 (2) , 51-52
Open AccessEditorial: The safety and efficacy of ustekinumab in anti-TNFα refractory pediatric inflammatory bowel disease
- Open Access
The Specific Carbohydrate Diet and Diet Modification as Induction Therapy for Pediatric Crohn’s Disease: A Randomized Diet Controlled Trial
Background: Crohn’s disease (CD) is a chronic inflammatory intestinal disorder associated with intestinal dysbiosis. Diet modulates the intestinal microbiome and therefore has a therapeutic potential. The aim of this study is to determine the potential efficacy of three versions of the specific carbohydrate diet (SCD) in active Crohn’s Disease. Methods: 18 patients with mild/moderate CD (PCDAI 15–45) aged 7 to 18 years were enrolled. Patients were randomized to either SCD, modified SCD(MSCD) or whole foods (WF) diet. Patients were evaluated at baseline, 2, 4, 8 and 12 weeks. PCDAI, inflammatory labs and multi-omics evaluations were assessed. Results: Mean age was 14.3 ± 2.9 years. At week 12, all participants (n = 10) who completed the study achieved clinical remission. The C-reactive protein decreased from 1.3 ± 0.7 at enrollment to 0.9 ± 0.5 at 12 weeks in the SCD group. In the MSCD group, the CRP decreased from 1.6 ± 1.1 at enrollment to 0.7 ± 0.1 at 12 weeks. In the WF group, the CRP decreased from 3.9 ± 4.3 at enrollment to 1.6 ± 1.3 at 12 weeks. In addition, the microbiome composition shifted in all patients across the study period. While the nature of the changes was largely patient specific, the predicted metabolic mode of the organisms increasing and decreasing in activity was consistent across patients. Conclusions: This study emphasizes the impact of diet in CD. Each diet had a positive effect on symptoms and inflammatory burden; the more exclusionary diets were associated with a better resolution of inflammation.
Open AccessThe Specific Carbohydrate Diet and Diet Modification as Induction Therapy for Pediatric Crohn’s Disease: A Randomized Diet Controlled Trial
Background: Crohn’s disease (CD) is a chronic inflammatory intestinal disorder associated with intestinal dysbiosis. Diet modulates the intestinal microbiome and therefore has a therapeutic potential. The aim of this study is to determine the potential efficacy of three versions of the specific carbohydrate diet (SCD) in active Crohn’s Disease. Methods: 18 patients with mild/moderate CD (PCDAI 15–45) aged 7 to 18 years were enrolled. Patients were randomized to either SCD, modified SCD(MSCD) or whole foods (WF) diet. Patients were evaluated at baseline, 2, 4, 8 and 12 weeks. PCDAI, inflammatory labs and multi-omics evaluations were assessed. Results: Mean age was 14.3 ± 2.9 years. At week 12, all participants (n = 10) who completed the study achieved clinical remission. The C-reactive protein decreased from 1.3 ± 0.7 at enrollment to 0.9 ± 0.5 at 12 weeks in the SCD group. In the MSCD group, the CRP decreased from 1.6 ± 1.1 at enrollment to 0.7 ± 0.1 at 12 weeks. In the WF group, the CRP decreased from 3.9 ± 4.3 at enrollment to 1.6 ± 1.3 at 12 weeks. In addition, the microbiome composition shifted in all patients across the study period. While the nature of the changes was largely patient specific, the predicted metabolic mode of the organisms increasing and decreasing in activity was consistent across patients. Conclusions: This study emphasizes the impact of diet in CD. Each diet had a positive effect on symptoms and inflammatory burden; the more exclusionary diets were associated with a better resolution of inflammation.
- 1 December 2020
- Published by Elsevier in Gastroenterology Clinics of North America
- Vol. 49 (4) , 655-669
Ulcerative Colitis
- 1 December 2020
- Published by Elsevier in Gastroenterology Clinics of North America
- Vol. 49 (4) , 655-669
Ulcerative Colitis
- 21 March 2020
- Published by Springer Nature
- p. 205-220
Gastrointestinal and Hepatic Issues in Women with Turner Syndrome
- 21 March 2020
- Published by Springer Nature
- p. 205-220
Gastrointestinal and Hepatic Issues in Women with Turner Syndrome
- 1 October 2016
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 51 (10) , 1674-1679
Resource utilization after implementing a hospital-wide standardized feeding tube placement pathway
- 1 October 2016
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 51 (10) , 1674-1679
Resource utilization after implementing a hospital-wide standardized feeding tube placement pathway
- 1 September 2016
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 63 (3) , 348-351
Ustekinumab in Pediatric Crohn Disease Patients
Objectives: We describe the use of ustekinumab for 4 patients with pediatric Crohn disease treated at the Seattle Children's Hospital Inflammatory Bowel Disease Center.Methods: A retrospective chart review was done to identify patients’ clinical data, disease phenotype, treatment history, and laboratory and growth parameters before treatment with ustekinumab and at last follow‐up. Adverse events while on ustekinumab were also recorded.Results: Four adolescent patients with Crohn disease at our center received ustekinumab. All had previously received corticosteroids, methotrexate, azathioprine/6‐mercaptopurine, and both infliximab and adalimumab. Patients had varying disease phenotypes. Ages at ustekinumab initiation were 12, 13, 16, and 17 years. Weight ranged from 40.5 to 57.8 kg, mean 49.5 kg. Two patients showed clinical response and remain on ustekinumab. Two patients discontinued therapy because of continued symptoms and disease complications and required multiple hospitalizations.Conclusions: Ustekinumab was used in 4 children with pediatric Crohn disease with 2 of 4 patients showing clinical response (1 with persistently elevated C‐reactive protein). A prospective study is needed to define its efficacy, safety, and placement in managing pediatric Crohn disease in the future.
- 1 September 2016
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 63 (3) , 348-351
Ustekinumab in Pediatric Crohn Disease Patients
Objectives: We describe the use of ustekinumab for 4 patients with pediatric Crohn disease treated at the Seattle Children's Hospital Inflammatory Bowel Disease Center.Methods: A retrospective chart review was done to identify patients’ clinical data, disease phenotype, treatment history, and laboratory and growth parameters before treatment with ustekinumab and at last follow‐up. Adverse events while on ustekinumab were also recorded.Results: Four adolescent patients with Crohn disease at our center received ustekinumab. All had previously received corticosteroids, methotrexate, azathioprine/6‐mercaptopurine, and both infliximab and adalimumab. Patients had varying disease phenotypes. Ages at ustekinumab initiation were 12, 13, 16, and 17 years. Weight ranged from 40.5 to 57.8 kg, mean 49.5 kg. Two patients showed clinical response and remain on ustekinumab. Two patients discontinued therapy because of continued symptoms and disease complications and required multiple hospitalizations.Conclusions: Ustekinumab was used in 4 children with pediatric Crohn disease with 2 of 4 patients showing clinical response (1 with persistently elevated C‐reactive protein). A prospective study is needed to define its efficacy, safety, and placement in managing pediatric Crohn disease in the future.
- 1 May 2016
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 62 (5) , 728-733
Precolectomy Therapy Does Not Alter Histologic Findings Distribution in Resected Colon in Pediatric Ulcerative Colitis
Objectives: Medically intractable pediatric ulcerative colitis can lead to colectomy after which patients commonly receive an ileoanal pouch. Postoperative complications are more common in patients with Crohn disease, a diagnosis that may be rendered after the colectomy specimen is examined. Because most children are likely to be exposed to medications before colectomy, we sought to examine whether such exposure influences the distribution of the inflammation within the resected colon and therefore potentially raise questions about the diagnosis accuracy. Methods: We conducted a retrospective cohort study of 32 pediatric ulcerative colitis cases undergoing colectomy from 2007 to 2014 for clinical data and precolectomy treatment history. The resected colon histology was reviewed independently by 2 blinded pathologists. The acute/active inflammation was scored using the modified Riley score for 3 colonic segments (proximal, transverse, and distal colon) for each patient. Linear mixed-effects models were used to evaluate possible association between acute/active inflammation scores at various sites and medication use. Results: Twelve cases (38%) showed decreasing acute inflammation score distally to proximally, 8 (25%) had increasing scores, and 12 cases showed no change. Patients were most commonly exposed to corticosteroids, followed by anti-tumor necrosis factor antibodies. There was no statistically or clinically significant change in the histologic scores across the colonic segments of the resected colon in association with exposure to any specific medication or combination of medications, sex, age at diagnosis and surgery, or duration of disease. Conclusions: Precolectomy therapy does not seem to influence the distribution of inflammation within the resected colon.
- 1 May 2016
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 62 (5) , 728-733
Precolectomy Therapy Does Not Alter Histologic Findings Distribution in Resected Colon in Pediatric Ulcerative Colitis
Objectives: Medically intractable pediatric ulcerative colitis can lead to colectomy after which patients commonly receive an ileoanal pouch. Postoperative complications are more common in patients with Crohn disease, a diagnosis that may be rendered after the colectomy specimen is examined. Because most children are likely to be exposed to medications before colectomy, we sought to examine whether such exposure influences the distribution of the inflammation within the resected colon and therefore potentially raise questions about the diagnosis accuracy. Methods: We conducted a retrospective cohort study of 32 pediatric ulcerative colitis cases undergoing colectomy from 2007 to 2014 for clinical data and precolectomy treatment history. The resected colon histology was reviewed independently by 2 blinded pathologists. The acute/active inflammation was scored using the modified Riley score for 3 colonic segments (proximal, transverse, and distal colon) for each patient. Linear mixed-effects models were used to evaluate possible association between acute/active inflammation scores at various sites and medication use. Results: Twelve cases (38%) showed decreasing acute inflammation score distally to proximally, 8 (25%) had increasing scores, and 12 cases showed no change. Patients were most commonly exposed to corticosteroids, followed by anti-tumor necrosis factor antibodies. There was no statistically or clinically significant change in the histologic scores across the colonic segments of the resected colon in association with exposure to any specific medication or combination of medications, sex, age at diagnosis and surgery, or duration of disease. Conclusions: Precolectomy therapy does not seem to influence the distribution of inflammation within the resected colon.
- Open Access
- 1 January 2016
- Published by Medknow in Saudi Journal of Gastroenterology
- Vol. 22 (2) , 89-90
Growth parameters early in the course of pediatric inflammatory bowel disease
- 1 January 2016
- Published by Medknow in Saudi Journal of Gastroenterology
- Vol. 22 (2) , 89-90
Open AccessGrowth parameters early in the course of pediatric inflammatory bowel disease
- 1 March 2013
- Published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology
- Vol. 7 (3) , 215-223
The pediatric pouch in inflammatory bowel disease: a primer for the gastroenterologist
Pediatric severe ulcerative colitis that is resistant to current medical treatment can successfully be managed surgically with a colectomy, ileal pouch creation and pouch-anal anastomosis. Key issues that should be considered and discussed before the pouch option can be offered include alternative surgical procedures, pouch function expectations, risk of surgical leak, pelvic sepsis, anastomotic strictures, acute and chronic pouch inflammation, Crohn's disease of the pouch and risk of reduced fertility for females. A long-term risk is malignancy of the residual colonic tissue. The decision to proceed with a pouch or not poses a substantial emotional burden to the child and family. Despite the risk of surgical complications and pouch inflammatory and functional challenges, the overwhelming majority of children and their families are satisfied with their pouch surgery outcomes. Further study is needed to assess preoperative risk predictors, prevention and treatment of complications.
- 1 March 2013
- Published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology
- Vol. 7 (3) , 215-223
The pediatric pouch in inflammatory bowel disease: a primer for the gastroenterologist
Pediatric severe ulcerative colitis that is resistant to current medical treatment can successfully be managed surgically with a colectomy, ileal pouch creation and pouch-anal anastomosis. Key issues that should be considered and discussed before the pouch option can be offered include alternative surgical procedures, pouch function expectations, risk of surgical leak, pelvic sepsis, anastomotic strictures, acute and chronic pouch inflammation, Crohn's disease of the pouch and risk of reduced fertility for females. A long-term risk is malignancy of the residual colonic tissue. The decision to proceed with a pouch or not poses a substantial emotional burden to the child and family. Despite the risk of surgical complications and pouch inflammatory and functional challenges, the overwhelming majority of children and their families are satisfied with their pouch surgery outcomes. Further study is needed to assess preoperative risk predictors, prevention and treatment of complications.
- Open Access
- 1 January 2009
- Published by Springer Nature in Cases Journal
- Vol. 2 (1) , 7511
Collagenous gastritis, a new spectrum of disease in pediatric patients: two case reports
Collagenous gastritis is a rare gastrointestinal disorder characterized in pediatrics by abdominal pain and anemia. The literature divides collagenous gastritis into distinct pediatric-onset and adult-onset phenotypes. As opposed to pediatric form, the adult form is associated with collagenous colitis and presents clinically with voluminous non-bloody diarrhea. There are over 25 case reports of collagenous gastritis of which 10 are pediatric cases. We present two cases of pediatric onset collagenous gastritis: one with a classic pediatric presentation, the other with findings typical of adult-onset disease. This is the first report of the adult-onset phenotype collagenous gastritis in a pediatric patient.
- 1 January 2009
- Published by Springer Nature in Cases Journal
- Vol. 2 (1) , 7511
Open AccessCollagenous gastritis, a new spectrum of disease in pediatric patients: two case reports
Collagenous gastritis is a rare gastrointestinal disorder characterized in pediatrics by abdominal pain and anemia. The literature divides collagenous gastritis into distinct pediatric-onset and adult-onset phenotypes. As opposed to pediatric form, the adult form is associated with collagenous colitis and presents clinically with voluminous non-bloody diarrhea. There are over 25 case reports of collagenous gastritis of which 10 are pediatric cases. We present two cases of pediatric onset collagenous gastritis: one with a classic pediatric presentation, the other with findings typical of adult-onset disease. This is the first report of the adult-onset phenotype collagenous gastritis in a pediatric patient.